AVTRMEDIUM SIGNALFINANCIAL10-K

AVTR shows mixed financial performance with improved liquidity position but declining cash generation from operations.

The company strengthened its balance sheet through higher cash reserves and reduced current liabilities, suggesting improved short-term financial flexibility. However, the notable decline in operating cash flow raises questions about the sustainability of operational performance and cash generation capabilities.

Comparing 2026-02-11 vs 2025-02-07View on EDGAR →
FINANCIAL ANALYSIS

AVTR's balance sheet improved meaningfully with cash increasing 39.5% to $365.4M and current liabilities declining 31.3% to $1.4B, creating a stronger liquidity position. Current assets grew modestly to $2.5B with inventory up 11.9%, indicating stable working capital management. The concerning element is operating cash flow declining 25.8% to $623.8M, which suggests operational headwinds despite the improved balance sheet metrics.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+39.5%
$261.9M$365.4M

Cash position surged 39.5% — strong cash generation or capital raise providing significant financial cushion.

Current Liabilities
Balance Sheet
-31.3%
$2.0B$1.4B

Current liabilities reduced — improved short-term financial position and working capital health.

Operating Cash Flow
Cash Flow
-25.8%
$840.8M$623.8M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Current Assets
Balance Sheet
+14.2%
$2.1B$2.5B

Current assets grew 14.2% — improving short-term liquidity or inventory/receivables build.

Inventory
Balance Sheet
+11.9%
$731.5M$818.2M

Inventory built 11.9% — monitor whether demand supports this build or if write-downs may follow.

LANGUAGE CHANGES
NEW — 2026-02-11
PRIOR — 2025-02-07
ADDED
On February 5, 2026, 682,055,932 shares of common stock, $0.01 par value per share, were outstanding.
We are a leading global provider of mission-critical products and services to customers in the biopharma healthcare, education government, and advanced technologies applied materials end markets.
First, in our channel business, VWR, we distribute consumables and equipment to laboratories around the world.
Second, we manufacture proprietary products used in life sciences and medical technology applications.
The VWR channel includes a private label offering that enables more than 5,000 suppliers to provide products using the VWR label; millions of SKUs from the most renowned life sciences suppliers in the world; and value-add services where approximately 2,000 of our associates work alongside our customers to ensure scientists can focus on what they do best.
+7 more — sign up free →
REMOVED
On February 3, 2025, 680,902,572 shares of common stock, $0.01 par value per share, were outstanding.
We are a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education government, and advanced technologies applied materials industries.
Our comprehensive offering provides scientists all they need to conduct their research: materials consumables, equipment instrumentation and services specialty procurement.
Our broad portfolio of products and services, fully integrated business model and global supply chain enable us to support our customers journey every step of the way.
Our e-commerce platform makes it easy for customers to do business with us and enables digital marketing efforts that position us to capture new demand.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →